ASO

isolved Named a Leader in NelsonHall's Digital Payroll Capabilities Evaluation

Retrieved on: 
Thursday, November 9, 2023

CHARLOTTE, N.C., Nov. 9, 2023 /PRNewswire/ -- On the heels of its most-successful HR Tech Conference, NAPEO Conference and annual customer and partner conference, Connect, isolved has announced its Leader positioning in an independent, third-party analyst evaluation for payroll. isolved has been named a Leader in the NelsonHall Vendor Evaluation & Assessment Tool (NEAT) for Payroll Services 2023 with Digital Payroll Capability. This recognition serves as further proof of isolved's commitment to both the customers it serves directly and the administrative service organizations (ASO), professional employer organizations (PEO) and payroll service providers (PSP) exclusively offering isolved People Cloud to their clients.

Key Points: 
  • isolved has been named a Leader in the NelsonHall Vendor Evaluation & Assessment Tool (NEAT) for Payroll Services 2023 with Digital Payroll Capability .
  • SMB Expertise: With a large client base and expertise in the small- and medium-sized business (SMB) market, the evaluation highlights isolved's capabilities for this business segment.
  • "isolved is a Leader in the Digital Payroll Capability market segment for its ongoing innovation, advanced predictive analytics and responsive customer service," said Liz Rennie, NelsonHall's HR Technology & Services Research Director.
  • isolved Perfect Payroll™ was overviewed as well – spotting anomalies in payroll and showing prescriptive guidance to make payroll smarter and error-free.

Charles River Laboratories’ Industry Experts to Present Advanced Modalities at Neuroscience 2023

Retrieved on: 
Thursday, November 9, 2023

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 19 scientific posters, both independently and collaboratively with clients, at Neuroscience 2023, the annual meeting of the Society for Neuroscience (SfN).

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 19 scientific posters, both independently and collaboratively with clients, at Neuroscience 2023, the annual meeting of the Society for Neuroscience (SfN).
  • “Neuroscience is one of the most complex areas of drug discovery,” Antti Nurmi, PhD, MSc, Regional General Manager, Europe, Charles River.
  • These innovations will ultimately accelerate success in this critical field of drug development.”
    Throughout the conference, Charles River experts will present posters and host discussions on the latest developments in neuroscience research and innovative approaches to tackling neurodegenerative disorders.
  • Additionally, experts will be available at Booth #1717 for meetings with those interested in discussing neuroscience research and drug discovery.

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, November 7, 2023

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the third quarter ended September 30, 2023, and provided business highlights.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the third quarter ended September 30, 2023, and provided business highlights.
  • Denali has selected five ASO targets for further development and is focused on advancing two OTV candidates towards clinical development.
  • 2023 Guidance on Operating Expenses:
    Cash, cash equivalents, and marketable securities were approximately $1.12 billion as of September 30, 2023.
  • General and administrative expenses were $25.3 million and $23.3 million for the three months ended September 30, 2023 and 2022, respectively.

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer

Retrieved on: 
Tuesday, November 7, 2023

NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS”) and its majority-owned subsidiary, Duet BioTherapeutics Inc., presented compelling new data that DUET-102 in combination with PD-1 blockade demonstrates significant anti-tumor activity in models of malignant glioma.

Key Points: 
  • DUET-102 is a double-stranded antisense oligonucleotide (“ASO”) STAT3 inhibitor linked to a TLR9 immune activator being developed for the treatment of glioma.
  • Glioma is a common type of tumor originating in the glial cells of the brain.
  • DUET-102, as a monotherapy, inhibited tumor growth and extended survival of mice in U251, GL261, and QPP8 models of glioma.
  • There is an acute need for new treatment options for glioma, which have seen no significant advances in the past decade.

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, November 7, 2023

These data, along with encouraging feedback from clinicians, support our belief that STK-001 is a disease-modifying approach that is moving treatment beyond seizure management to address the syndrome.

Key Points: 
  • These data, along with encouraging feedback from clinicians, support our belief that STK-001 is a disease-modifying approach that is moving treatment beyond seizure management to address the syndrome.
  • Following an analysis of these data, the Company plans to meet with regulators to discuss a Phase 3 study design.
  • As of September 30, 2023, Stoke had $214.7 million in cash, cash equivalents, and marketable securities, which is anticipated to fund operations to the end of 2025.
  • General and administrative expenses for the nine months ended September 30, 2023, were $30.7 million, compared to $29.5 million for the same period in 2022.

EQS-News: Secarna Pharmaceuticals presents data at SITC demonstrating the potential of antisense oligonucleotides in targeting NRP1

Retrieved on: 
Tuesday, November 7, 2023

The data were presented at The Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting & Pre-Conference Programs (SITC 2023) in San Diego, which took place November 1 – 5, 2023.

Key Points: 
  • The data were presented at The Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting & Pre-Conference Programs (SITC 2023) in San Diego, which took place November 1 – 5, 2023.
  • As our LNA-modified ASOs potently reduce the expression of NRP1, all of these functions will be suppressed simultaneously.
  • Using the Company’s in-house Oligofyer™ system, Secarna designed locked nucleic acid (LNA) modified ASOs specifically targeting NRP1.
  • Secarna is currently planning studies to further delineate the proposed antitumor mechanisms of the NRP1 ASOs by spatial analysis of the tumor microenvironment.

Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones

Retrieved on: 
Monday, October 30, 2023

WALTHAM, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the third quarter of 2023 and provided an update on progress and upcoming milestones for its Phase 1/2 ACHIEVE and DELIVER clinical trials.

Key Points: 
  • (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the third quarter of 2023 and provided an update on progress and upcoming milestones for its Phase 1/2 ACHIEVE and DELIVER clinical trials.
  • “We’ve made tremendous progress in our ACHIEVE and DELIVER trials with more than 72 patients enrolled and over 300 doses administered thus far.
  • General and administrative (G&A) expenses: G&A expenses were $7.0 million for the quarter ended September 30, 2023, compared to $7.6 million for the quarter ended September 30, 2022.
  • Net loss: Net loss for the quarter ended September 30, 2023 was $60.2 million, or $0.99 per basic and diluted share.

EQS-News: Secarna Pharmaceuticals presents data at OTS showcasing unique characteristics and factors with a role in the activity and side effect profile of LNA-modified ASOs

Retrieved on: 
Thursday, October 26, 2023

The two posters were presented this week, at the 19th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.

Key Points: 
  • The two posters were presented this week, at the 19th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.
  • The poster 201: Characterization of immunostimulatory potential of LNA-modified antisense oligonucleotides was presented by Irene Riera Tur, PhD.
  • It could be shown that, among others, LNA-modified ASOs actually can induce activation of the human TLR9 pathway and downstream signaling.
  • “These data confirm our previous studies and convince us that we are on the right path to fully exploit the potential of ASOs.

New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease

Retrieved on: 
Wednesday, October 25, 2023

First study of a tau targeting drug that shows reduction of aggregated tau pathology and favorable trends on clinical outcomes.

Key Points: 
  • First study of a tau targeting drug that shows reduction of aggregated tau pathology and favorable trends on clinical outcomes.
  • CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in mild Alzheimer’s disease (AD).
  • The late-breaking results were presented at the 2023 Clinical Trials on Alzheimer’s Disease (CTAD) meeting held in Boston, MA from October 24-27.
  • The favorable trends suggest a potential link between a reduction in tau PET pathology and clinical outcomes.

Rockland Launches Novel Analytical Tools to Assess Drug Delivery: Revolutionizing Oligonucleotide Therapeutic Development

Retrieved on: 
Tuesday, October 17, 2023

LIMERICK, Pa., Oct. 17, 2023 /PRNewswire/ -- Rockland is a leading USA-based life science company, developing analytical tools that assist in the collection of pharmacodynamic, pharmacokinetic, and toxicology data critical for satisfying regulatory requirements for biological drugs, cell and gene therapies, and RNA therapeutic drugs (e.g., ASO, siRNA, mRNA). To date, Rockland has successfully generated reagents against many diverse nucleic acid chemical structures and modifications, including conventional oligonucleotides, DNA-RNA hybrids, single- and double-stranded RNA, and more.

Key Points: 
  • To date, Rockland has successfully generated reagents against many diverse nucleic acid chemical structures and modifications, including conventional oligonucleotides, DNA-RNA hybrids, single- and double-stranded RNA, and more.
  • Traditionally, ISH-type assays have been the mainstay method of detecting and localizing oligonucleotides in cells and tissues for nucleic acid therapy development.
  • Introducing the ModDetect™ Phosphorothioate (PS) Panel, an immunoassay-based alternative that provides robust detection of oligonucleotide therapeutic drug delivery and analysis, facilitating the collection of ADMET analytical data for regulatory approval.
  • ModDetect ™ is a growing suite of analytical tools generated against different types of nucleic acid chemical modifications.